Oracle Corporation
Investment Thesis
Oracle's post-earnings recovery to $188 presents a compelling short entry as the market has not fully priced in the structural headwinds: a $20B at-the-market equity issuance actively diluting shareholders, negative free cash flow through 2029, and 3.4x net debt/EBITDA threatening investment-grade credit status. The stock's inability to reclaim pre-earnings levels above $195-200 despite strong operational metrics confirms that rallies are being sold into, and the ongoing ATM equity program creates a persistent supply overhang that should cap upside and pressure shares over the next 2-3 months.
Why It May Work
Why It May Not Work
Timeline
CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.
We value your feedback — reporting errors helps us continuously improve.
Track This Trading Idea
Get real-time notifications when this idea hits milestones, receive high-impact news alerts, and track your portfolio performance.
Get Started FreeAlready have an account? Sign in